Human C-ERBB-2 proto-oncogene product as a target for bispecific-antibody-directed adoptive tumor immunotherapy

✍ Scribed by Takashi Nishimura; Yoshihiko Nakamura; Hideo Tsukamoto; Yasuhiro Takeuchi; Yutaka Tokuda; Megumi Iwasawa; Tadashi Yamamoto; Takashi Masuko; Yoshiyuki Hashimoto; Sonoko Habu

• Publisher: John Wiley and Sons
• Year: 1992
• Tongue: French
• Weight: 559 KB
• Volume: 50
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910500523

✦ Synopsis

To develop an efficient strategy for the targeting of antitumor effector cells, we prepared bispecific antibody (BsAb) containing anti-CD3 and an anti-c-erbB-2 proto-oncogene product. The prepared BsAb specifically reacts with both c-erb6-2positive tumor cells and CD3+ CTL. Human CD4' helper/killer T cells, induced from peripheral-blood mononuclear cells by activation with immobilized anti-CD3 monoclonal antibody (MAb) plus IL-2, showed no significant cytotoxicity against tumor cells. However, treatment of human CD4' helper/killer cells with the BsAb caused the induction of specific cytotoxicity against c-erb6-2-positive tumor cells. CD4+ helper/killer cells also produced significant amounts of IL-2 during co-culture with c-erb6-2-positive tumor cells in the presence of the BsAb. Moreover, by combination with the BsAb, CD4+ helper/killer cells showed a strong in vivo anti-tumor effect against c-erb6-2 transfectant or human colon-cancer cells implanted in nude mice. Our results strongly suggest that the c-erb6-2 protooncogene product on human tumor cells may be a good target for BsAb-directed adoptive tumor immunotherapy.

6To whom correspondence and reprint requests should be sent.